OBJECTIVE: To examine correlates of vaccine series completion among young adolescent US girls who initiated the human papillomavirus (HPV) vaccine. METHODS: We analyzed National Immunization Survey-Teens 2012 provider-verified data to examine correlates of HPV vaccine completion among 13- to 17-year-old girls who initiated HPV vaccine in 2012 (N = 4548). RESULTS: The weighted vaccine series completion rate among 13- to 17-year-old girl initiators was 66.7% (95% confidence interval [CI], 64.0-69.3). Adolescent girls who were older, residents of the Northeast (adjusted prevalence ratio [aPR], 1.36; 95% CI, 1.07-1.73), and had provider-verified seasonal influenza vaccination in the past year (aPR, 1.67; 95% CI, 1.32-2.11) and provider recommendation (aPR, 1.40; 95% CI, 1.10-1.77) were more likely to complete the 3-dose vaccine series. CONCLUSIONS: Parents of younger adolescent girls need to be educated about the importance of completing the 3-dose HPV vaccine series. Provider recommendation for the vaccine would also facilitate series completion.
OBJECTIVE: To examine correlates of vaccine series completion among young adolescent US girls who initiated the human papillomavirus (HPV) vaccine. METHODS: We analyzed National Immunization Survey-Teens 2012 provider-verified data to examine correlates of HPV vaccine completion among 13- to 17-year-old girls who initiated HPV vaccine in 2012 (N = 4548). RESULTS: The weighted vaccine series completion rate among 13- to 17-year-old girl initiators was 66.7% (95% confidence interval [CI], 64.0-69.3). Adolescent girls who were older, residents of the Northeast (adjusted prevalence ratio [aPR], 1.36; 95% CI, 1.07-1.73), and had provider-verified seasonal influenza vaccination in the past year (aPR, 1.67; 95% CI, 1.32-2.11) and provider recommendation (aPR, 1.40; 95% CI, 1.10-1.77) were more likely to complete the 3-dose vaccine series. CONCLUSIONS: Parents of younger adolescent girls need to be educated about the importance of completing the 3-dose HPV vaccine series. Provider recommendation for the vaccine would also facilitate series completion.
Authors: Susan Hariri; Elizabeth R Unger; Maya Sternberg; Eileen F Dunne; David Swan; Sonya Patel; Lauri E Markowitz Journal: J Infect Dis Date: 2011-08-15 Impact factor: 5.226
Authors: Charlene A Wong; Zahava Berkowitz; Christina G Dorell; Rebecca Anhang Price; Jennifer Lee; Mona Saraiya Journal: Cancer Date: 2011-06-20 Impact factor: 6.860
Authors: Eileen F Dunne; Elizabeth R Unger; Maya Sternberg; Geraldine McQuillan; David C Swan; Sonya S Patel; Lauri E Markowitz Journal: JAMA Date: 2007-02-28 Impact factor: 56.272
Authors: B Romanowski; P Colares de Borba; P S Naud; C M Roteli-Martins; N S De Carvalho; J C Teixeira; F Aoki; B Ramjattan; R M Shier; R Somani; S Barbier; M M Blatter; C Chambers; D Ferris; S A Gall; F A Guerra; D M Harper; J A Hedrick; D C Henry; A P Korn; R Kroll; A-B Moscicki; W D Rosenfeld; B J Sullivan; C S Thoming; S K Tyring; C M Wheeler; G Dubin; A Schuind; T Zahaf; Mary Greenacre; An Sgriobhadair Journal: Lancet Date: 2009-12-12 Impact factor: 79.321
Authors: Meg Watson; Mona Saraiya; Vicki Benard; Steven S Coughlin; Lisa Flowers; Vilma Cokkinides; Molly Schwenn; Youjie Huang; Anna Giuliano Journal: Cancer Date: 2008-11-15 Impact factor: 6.860
Authors: Suzanne M Garland; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Diane M Harper; Sepp Leodolter; Grace W K Tang; Daron G Ferris; Marc Steben; Janine Bryan; Frank J Taddeo; Radha Railkar; Mark T Esser; Heather L Sings; Micki Nelson; John Boslego; Carlos Sattler; Eliav Barr; Laura A Koutsky Journal: N Engl J Med Date: 2007-05-10 Impact factor: 91.245
Authors: Jennifer C Spencer; Noel T Brewer; Justin G Trogdon; Stephanie B Wheeler; Stacie B Dusetzina Journal: Am J Public Health Date: 2018-05-17 Impact factor: 9.308
Authors: Claire A Crawford; Ross Shegog; Lara S Savas; Erica L Frost; C Mary Healy; Sharon P Coan; Efrat K Gabay; Stanley W Spinner; Sally W Vernon Journal: J Appl Res Child Date: 2019